Galaxy Bag Technology Added Benefits Sustainability

FLEXBUMIN^®
ADDED BENEFITS

FLEXBUMIN^® offers several advantages & benefits compared to albumin in glass^5,12

Requires up to 48% less shelf space compared with albumin in glass^5,*
Weighs up to 56% less than albumin in glass^5,*

*50mL FLEXBUMIN^® GALAXY bag vs. 50mL Human Albumin glass bottles

Lower risk of shattering vs. glass¹²
No risk of interruption of care to clean up broken glass¹²
Ready for use in about 45 seconds¹²

FLEXBUMIN^® provides the choice of a closed infusion system in albumin therapy to help reduce CLABSI risks and patient mortality^2,6

In an observational study, 94% of participating nurses (N=36) stated they preferred using FLEXBUMIN^® albumin delivery system rather than Human Albumin bottles.^12,*

^*Based on an observational study performed with a total of 36 practicing nurses evaluating the way of use of FLEXBUMIN^® albumin delivery system vs. Human Albumin bottles with attached hangers or accompanying sleeves.¹²

SAVES SHELF SPACE^1-15

FAST, SIMPLE SETUP^1-15

REDUCED WASTE^1-15

DEVICE QUALITY

No latex used in the manufacture of the GALAXY container³
No known risk of aluminium leaching⁴
Resistance to degradation by oxidation²

CLOSED SYSTEM ASSET

Fully collapsible with self-sealing injection ports^1,2
Does not require external venting to empty, thus reducing the risk of external contamination^2,6
Sterile albumin solution without the need for port swabbing¹
Can limit residual volume wastage and medication error thanks to its collapsible system versus standard bottles¹¹

SUSTAINABILITY

Sustainable for a lower carbon footprint⁷
Storage at room temperature for 3 years (not to exceed 25°C)^1,2

HUMAN ALBUMIN QUALITY

Meets the Quality Standards of Excellence, Assurance and Leadership (QSEAL) albumin quality standards⁸

REFERENCES

Flexbumin^® India Prescribing Information (PI).
Four-layer bag technology - Ref-35896- Baxter - May 2017.
Flexbumin^® latex free statement-Internal Memo-January 2020.
Analysis of Aluminum levels in Flexbumin^® during stability - Internal Memo - July 2014.
Efficiency Weights and Dimensions of Albumin vs. Flexbumin^® - Internal Memo - 2017
Maki DG, et al. Impact of Switching from an Open to a Closed Infusion System on Rates of Central Line-Associated Bloodstream Infection: A Meta-analysis of Time-Sequence Cohort Studies in 4 Countries. Infect Control Hosp Epidemiol 2011:32-50-58
Carbon Trust Certification letter-Ref-38783-November 2014.
Plasma Protein Therapeutics Association. Quality Standards of Excellence, Assurance and Leadership (QSEAL) Available at: https://www.pptaglobal.org/material/quality-standards-of-excellence-assurance-and-leadership-qseal Accessed May 2025.
Baxalta US Inc. Flexbumin^® 25%, Albumin (Human), USP, 25% Solution. Package insert. Jul 2017. Available at: https://www.shirecontent.com/PI/PDFS/FLEXBUMIN25_USA_ENG.pdf. Accessed November 2020.
Baxalta US Inc. Flexbumin^® 5%, Albumin (Human) USP, 5% Solution. Package insert. July 2017. Available at: https://www.shirecontent.com/PI/PDFS/FLEXBUMINS USA ENG.adf. Accessed November 2020.
Štrbová P, et al. Residual volumes and final weights in different types of plastic infusion containers. Int J Pharm Sci. 2016:8(3):293-296.
Summary Report of Observations for Flexbumin^® bags and Buminate bottles. Shire, Data on file-ID: FLEX-005. July 2017.
Albumin packaged as Flexbumin^® and BUMINATE. Baxter Healthcare Corporation. Data on file. 2012.
Disposal cost assessment. Baxter Healthcare Corporation. Data on file, ref-34896. April 2010.
DOW. Saran PVDC Resins & Films and the Environment, DOW Form No. 190-00500-0305 March 2005

FLEXBUMIN®ADDED BENEFITS

SAVES SHELF SPACE1-15

FAST, SIMPLE SETUP1-15

REDUCED WASTE1-15